The Blog

Driving Simulation Study Conducted by Collaborative Neuroscience Research (CNS) Recently Published in Clinical and Translational Science

Apex’s partner for driving simulation studies, Cognitive Research Corporation, authored an article (https://doi.org/10.1111/cts.13145) about a clinical trial assessing the effect of Rapastinel on driving performance (NCT03814733). The trial, in which 107 healthy participants were enrolled, was conducted at two study centers including the Long Beach, CA location of Collaborative Neuroscience Research (CNS). The results of…

Read More

Apex Principal Investigators Author Article with Rovi

  Apex Principal Investigators, Drs. Howard Hassman and David Walling at Hassman Research Institute (HRI) and Collaborative Neuroscience Research (CNS), respectively, authored in collaboration with Rovi an article about a crucial clinical trial (NCT03527186) assessing the steady-state comparative bioavailability of risperidone in situ microimplants (ISM) and oral risperidone in 104 patients with schizophrenia. The study…

Read More

Apex Welcomes Tom Zoda, Ph.D. to its Executive Leadership Team

Bringing almost 30 years of experience in the pharmaceutical and clinical trials industry, Tom Zoda, Ph.D. has joined Apex Innovative Sciences as Chief Operating Officer. In his role as COO, Dr. Zoda will work with the executive team to develop and implement strategies to grow Apex as a market leader in the Phase I-III clinical…

Read More

Dr. Brett A. English Joins Apex as VP of Scientific Affairs

Apex Innovative Sciences Appoints Brett A. English, Pharm.D., Ph.D., as Vice President of Scientific Affairs MARLTON, N.J. and GARDEN GROVE, Calif., April 8, 2021 — Apex Innovative Sciences (“Apex”), an industry-leading independent provider of clinical drug development and trial site services, today announced the appointment of Brett A. English, Pharm.D., Ph.D., as Vice President of…

Read More

Dr. Larry Ereshefsky to Present at BioXcel’s Virtual KOL Event to Highlight BXCL501 as a Potential Treatment for Agitation

BioXcel Therapeutics, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of…

Read More

Dr. Larry Ereshefsky Coauthors Article on Cost-Effectiveness of MDD Treatment, Vortioxetine

Larry Ereshefsky, Pharm.D., Chief Scientific Officer of Apex Innovative Sciences, has published more than 130 peer-reviewed scholarly articles and abstracts. His latest work, “Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant,” has been published in the medical journal, Expert Review of Pharmacoeconomics & Outcomes…

Read More

2021 Pharma Conference eCards from Apex Innovative Sciences

Our annual eCards are here and updated for 2021. Download the neuroscience-focused card as well as the general medical version. We’re excited to connect with you during these conferences. Virtual and Zoom meetings will keep us safer for now, and we’re hopeful that we’ll return to in-person conversations in the near future. Please check each…

Read More

Apex Innovative Sciences Supports Three Major COVID-19 Vaccine Trials

MARLTON, N.J. and GARDEN GROVE, Calif., Jan. 5, 2021 — Apex Innovative Sciences (Apex) and its affiliates are proud to announce their participation in three COVID-19 vaccine studies. With East and West Coast operations and six state-of-the-art clinical trial facilities, Apex is strongly positioned to pivot from its core central nervous system (CNS) business and…

Read More

Dr. Howard Hassman Interviewed on The Price of Business Show

Howard Hassman, D.O., AOBFP discussed the formation of Apex Innovative Sciences, the COVID-19 vaccine studies conducted by Hassman Research Institute and CNS Research, and the use of psychedelics to treat a variety of disorders with Kevin Price, Host of The Price of Business Show. Listen to the interview in its entirety.

Read More

Neurana Pharmaceuticals Announces Positive Top-Line Results from Tolperisone Phase 1 CNS Effects Study Conducted by Apex Sites

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. The study, utilizing a validated driving test, confirmed that tolperisone does not impair driving performance. In addition, tolperisone does not appear to cause sleepiness, a side…

Read More
Page 1 of 1112 »